Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 857-861

  Merglen, A ^a   Verkooijen, H M ^a,b   Fioretta, G ^a   Neyroud Caspar, I ^a   Vinh Hung, V ^a,d   Vlastos, G ^c   Chappuis, P O ^c   Castiglione, M ^a   Rapiti, E ^a   Bouchardy, Christine ^a  

^a GENEVA CANCER REGISTRY   (Switzerland)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Breast cancer; Cancer registry; Hormonal therapy; Oestrogen receptor status; Survival

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HEALTH CARE SURVEYS; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RISK ASSESSMENT; SWITZERLAND; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 65549146892     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn688     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
3. Roila F, Ballatori E, Patoia L et al. Adjuvant systemic therapies in women with breast cancer: An audit of clinical practice in Italy. Ann Oncol 2003; 14: 843-848.
4. World Health Organization (WHO). ICD-10. International Statistical Classification of Diseases and Health Related Problems. 10th revision. Geneva: World Health Organization 1992.
5. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, 6th edition. New York: UICC 2002.
6. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
7. Fisher B, Redmond C, Brown A et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983; 1: 227-241.
8. Hutchins LF, Green SJ, Ravdin PM et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: Treatment results of Intergroup Protocol INT-0102. J Clin Oncol 2005; 23: 8313-8321.
9. Kaufmann M, Graf E, Jonat W et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: A randomized trial (GABG-IV D-93) - the German Adjuvant Breast Cancer Group. J Clin Oncol 2005; 23: 7842-7848.
10. Colleoni M, Gelber S, Goldhirsch A et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
11. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818-826.
12. Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: An alternative hypothesis. Breast Cancer Res 2005; 7: R1153-R1158.
13. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846-3852.
14. Gruvberger-Saal SK, Bendahl PO, Saal LH et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13: 1987-1994.
15. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008; 100: 218-221.
16. Nicholson RI, Hutcheson IR, Jones HE et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007; 8: 241-253.
17. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6: 373-387.
18. Singh MN, Stringfellow HF, Paraskevaidis E et al. Tamoxifen: Important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 2007; 33: 91-100.
19. Barkhem T, Carlsson B, Nilsson Y et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 1998; 54: 105-112.
20. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
21. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
22. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11: 4741-4748.
23. Dhesy-Thind B, Pritchard KI, Messersmith H et al. HER2/neu in systemic therapy for women with breast cancer: A systematic review. Breast Cancer Res Treat 2008; 109: 209-229.
24. Ellis MJ, Rosen E, Dressman H, Marks J. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: Pretreatment determinants of response and ontreatment effect. J Steroid Biochem Mol Biol 2003; 86: 301-307.
25. Jordan VC. Is tamoxifen the Rosetta stone for breast cancer? J Natl Cancer Inst 2003; 95: 338-340.
26. Ryden L, Landberg G, Stal O et al. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 2008; 109: 351-357.
27. Colozza M, de Azambuja E, Cardoso F et al. Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006; 11: 111-125.
28. Estevez LG, Munoz M, Alvarez I et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev 2007; 33: 474-483.
29. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
30. Thurlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 (8 Suppl): viii8-viii17.